blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3110846

EP3110846 - ANTIBODIES THAT BIND EGFR AND ERBB3 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.06.2021
Database last updated on 22.08.2024
FormerThe patent has been granted
Status updated on  17.07.2020
FormerGrant of patent is intended
Status updated on  01.04.2020
FormerExamination is in progress
Status updated on  13.10.2017
FormerRequest for examination was made
Status updated on  02.12.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Merus N.V.
Yalelaan 62
3584 CM Utrecht / NL
[2017/06]
Former [2017/01]For all designated states
Merus N.V.
Padualaan 8, postvak 133
3584 CH Utrecht / NL
Inventor(s)01 / LOGTENBERG, Ton
c/o Yalelaan 62
3584 CM Utrecht / NL
02 / THROSBY, Mark
c/o Yalelaan 62
3584 CM Utrecht / NL
03 / ROOVERS, Robertus Cornelis
c/o Yalelaan 62
3584 CM Utrecht / NL
 [2020/20]
Former [2017/01]01 / LOGTENBERG, Ton
c/o Padualaan 8
Postvak 133
NL-3584 CH Utrecht / NL
02 / THROSBY, Mark
c/o Padualaan 8
Postvak 133
NL-3584 CH Utrecht / NL
03 / ROOVERS, Robertus Cornelis
c/o Padualaan 8
Postvak 133
NL-3584 CH Utrecht / NL
Representative(s)V.O.
P.O. Box 87930
Carnegieplein 5
2508 DH Den Haag / NL
[2017/01]
Application number, filing date15708906.127.02.2015
[2017/01]
WO2015NL50124
Priority number, dateEP2014015735128.02.2014         Original published format: EP 14157351
[2017/01]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015130172
Date:03.09.2015
Language:EN
[2015/35]
Type: A1 Application with search report 
No.:EP3110846
Date:04.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.2015 takes the place of the publication of the European patent application.
[2017/01]
Type: B1 Patent specification 
No.:EP3110846
Date:19.08.2020
Language:EN
[2020/34]
Search report(s)International search report - published on:EP03.09.2015
ClassificationIPC:C07K16/28, C07K16/32
[2017/01]
CPC:
C07K16/2863 (EP,US); A61P35/00 (EP); A61P35/04 (EP);
C07K16/32 (EP,US); C07K2317/31 (EP,US); C07K2317/565 (US);
C07K2317/732 (US); C07K2317/76 (US); C07K2317/92 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/01]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:EGFR- UND ERBB3-BINDENDE ANTIKÖRPER[2017/01]
English:ANTIBODIES THAT BIND EGFR AND ERBB3[2017/01]
French:ANTICORPS QUI SE LIENT AUX EGFR ET ERBB3[2020/17]
Former [2017/01]ANTICORPS QUI SE LIENT À L'EGFR ET À L'ERBB3
Entry into regional phase22.09.2016National basic fee paid 
22.09.2016Designation fee(s) paid 
22.09.2016Examination fee paid 
Examination procedure22.09.2016Examination requested  [2017/01]
22.09.2016Date on which the examining division has become responsible
06.04.2017Amendment by applicant (claims and/or description)
16.10.2017Despatch of a communication from the examining division (Time limit: M06)
26.04.2018Reply to a communication from the examining division
30.07.2018Despatch of a communication from the examining division (Time limit: M06)
08.03.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
30.04.2019Reply to a communication from the examining division
16.03.2020Cancellation of oral proceeding that was planned for 17.03.2020
17.03.2020Date of oral proceedings (cancelled)
02.04.2020Communication of intention to grant the patent
10.07.2020Fee for grant paid
10.07.2020Fee for publishing/printing paid
10.07.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20190908.2  / EP3786186
Opposition(s)20.05.2021No opposition filed within time limit [2021/30]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
30.04.2019Request for further processing filed
30.04.2019Full payment received (date of receipt of payment)
Request granted
14.05.2019Decision despatched
Fees paidRenewal fee
31.01.2017Renewal fee patent year 03
31.01.2018Renewal fee patent year 04
22.01.2019Renewal fee patent year 05
21.01.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.02.2015
AL19.08.2020
AT19.08.2020
CY19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
MK19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
LU27.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
[2024/22]
Former [2023/30]HU27.02.2015
AL19.08.2020
AT19.08.2020
CY19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
LU27.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2023/27]HU27.02.2015
AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
LU27.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2022/34]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
LU27.02.2021
BE28.02.2021
CH28.02.2021
LI28.02.2021
Former [2021/47]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
LU27.02.2021
CH28.02.2021
LI28.02.2021
Former [2021/41]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
MC19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/36]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SI19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/28]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SK19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/25]AL19.08.2020
AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/23]AT19.08.2020
CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
SM19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/22]CZ19.08.2020
DK19.08.2020
EE19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RO19.08.2020
RS19.08.2020
SE19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/20]DK19.08.2020
FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RS19.08.2020
SE19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/10]FI19.08.2020
HR19.08.2020
LT19.08.2020
LV19.08.2020
PL19.08.2020
RS19.08.2020
SE19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
IS19.12.2020
PT21.12.2020
Former [2021/09]FI19.08.2020
LT19.08.2020
SE19.08.2020
BG19.11.2020
NO19.11.2020
GR20.11.2020
PT21.12.2020
Former [2021/08]FI19.08.2020
LT19.08.2020
SE19.08.2020
BG19.11.2020
NO19.11.2020
PT21.12.2020
Former [2021/07]FI19.08.2020
LT19.08.2020
NO19.11.2020
Cited inInternational search[A]US2004071696  (ADAMS GREGORY P [US], et al) [A] 1-29* claims 1-65 *;
 [A]WO2008140493  (UNIV CALIFORNINA [US], et al) [A] 1-29 * paragraphs [0090] , [0096]; claims 1-66 *;
 [X]WO2010108127  (GENENTECH INC [US], et al) [X] 1-29 * examples 5-19; claims 1-37 *;
 [I]US2013259867  (AMLER LUKAS [US], et al) [I] 1-29 * examples 1-5 *;
 [I]  - SCHAEFER G ET AL, "A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies", CANCER CELL, CELL PRESS, US, (20111018), vol. 20, no. 4, doi:10.1016/J.CCR.2011.09.003, ISSN 1535-6108, pages 472 - 486, XP002694584 [I] 1-29 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ccr.2011.09.003
by applicantUS2003078385
 WO2004009618
 WO2008027236
 WO2009157771
 US2010183615
 WO2010108127
 EP2604625
 WO2013157954
    - JUNTTILA, T. T.; K. PARSONS ET AL., "Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer.", CANCER RESEARCH, (2010), vol. 70, no. 11, doi:doi:10.1158/0008-5472.CAN-09-3704, pages 4481 - 4489, XP002741171

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-3704
    - SCHAEFER ET AL., CANCER CELL, (201110), vol. 20, pages 472 - 486
    - OLAYIOYE MA ET AL., EMBO J, (2000), vol. 19, pages 3159 - 3167
    - CANCER SCI., (200909), vol. 100, no. 9, pages 1566 - 72
    - J.C. ALMAGROL; J. FRANSSON, FRONTIERS IN BIOSCIENCE, (2008), vol. 13, pages 1619 - 1633
    - GUNASEKARAN, JBC, (2010), vol. 285, pages 19637 - 19646
    - SHAMES ET AL., PLOS ONE, (201302), vol. 8, no. 2, pages 1 - 10
    - YONESAKA ET AL., SCI.TRANSL.MED., (2011), vol. 3, no. 99, page 11
    - YONESAKA ET AL., SCI.TRANSL.MED., (2011), vol. 3, no. 99, page L-11
    - SCHMITZ, K.R.; K.M. FERGUSON, "Interaction of antibodies with ErbB receptor extracellular regions", EXP CELL RES, (2009), vol. 315, no. 4, doi:doi:10.1016/j.yexcr.2008.10.008, pages 659 - 70, XP025929171

DOI:   http://dx.doi.org/10.1016/j.yexcr.2008.10.008
    - DE HAARD, H.J. ET AL., "A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies", J BIOL CHEM, (1999), vol. 274, no. 26, doi:doi:10.1074/jbc.274.26.18218, pages 18218 - 30, XP002128301

DOI:   http://dx.doi.org/10.1074/jbc.274.26.18218
    - MARKS, J.D. ET AL., "By-passing immunization. Human antibodies from V gene libraries displayed on phage", J MOL BIOL, (1991), vol. 222, no. 3, doi:doi:10.1016/0022-2836(91)90498-U, pages 581 - 97, XP024010124

DOI:   http://dx.doi.org/10.1016/0022-2836(91)90498-U
    - MEULEMANS, E.V. ET AL., "Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibod", J MOL BIOL, (1994), vol. 244, no. 4, doi:doi:10.1006/jmbi.1994.1735, pages 353 - 60, XP024009278

DOI:   http://dx.doi.org/10.1006/jmbi.1994.1735
    - GIARD, D.J. ET AL., "In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors", J NATL CANCER INST, (1973), vol. 51, no. 5, pages 1417 - 23, XP009085989
    - MERLINO, G.T. ET AL., "Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells", SCIENCE, (1984), vol. 224, no. 4647, pages 417 - 9
    - COCHRAN, J.R. ET AL., "Domain-level antibody epitope mapping through yeast surface display of epidermal growth factor receptor fragments", J IMMUNOL METHODS, (2004), vol. 287, no. 1-2, doi:doi:10.1016/j.jim.2004.01.024, pages 147 - 58, XP004503477

DOI:   http://dx.doi.org/10.1016/j.jim.2004.01.024
    - LEDON, N. ET AL., "Comparative analysis of binding affinities to epidermal growth factor receptor of monoclonal antibodies nimotuzumab and cetuximab using different experimental animal models", PLACENTA, (2011), vol. 32, no. 7, doi:doi:10.1016/j.placenta.2011.04.008, pages 531 - 4, XP028228236

DOI:   http://dx.doi.org/10.1016/j.placenta.2011.04.008
    - GULLI, L.F. ET AL., "Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity", CELL GROWTH DIFFER, (1996), vol. 7, no. 2, pages 173 - 8
    - PASTORE S; MASCIA F; MARIOTTI F; DATTILO C; MARIANI V; GIROLOMONI G, "ERK1/2 regulates epidermal chemokine expression and skin inflammation", IMMUNOL., (2005), vol. 174, no. 8, pages 5047 - 5056, XP002410415
    - LICHTENBERGER BM; GERBER P A.; HOLCMANN M ET AL., "Epidermal EGFR Controls Cutaneous Host Defense and Prevents Inflammation", SCI TRANSL MED., (2013), vol. 5, pages 199RA111 - 199RA111
    - CHENG LIU; ANDREIA LEE, "ADCC Enhancement Technologies for Next Generation Therapeutic Antibody", ANTIBODY THERAPEUTICS -TRENDS IN BIO/PHARMACEUTICAL INDUSTRY, (2009), pages 13 - 17
    - GARRETT TP; MCKERN NM; LOU M; ELLEMAN TC; ADAMS TE; LOVRECZ GO; ZHU HJ; WALKER F; FRENKEL MJ; HOYNE PA, "Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha", CELL, (2002), vol. 110, doi:doi:10.1016/S0092-8674(02)00940-6, pages 763 - 73, XP002229457

DOI:   http://dx.doi.org/10.1016/S0092-8674(02)00940-6
    - OGISO H; ISHITANI R; NUREKI O; FUKAI S; YAMANAKA M; KIM JH; SAITO K; SAKAMOTO A; INOUE M; SHIROUZU M, "Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains", CELL, (2002), vol. 110, doi:doi:10.1016/S0092-8674(02)00963-7, pages 775 - 87, XP002961395

DOI:   http://dx.doi.org/10.1016/S0092-8674(02)00963-7
    - FERGUSON KM, "Structure-based view of epidermal growth factor receptor regulation", ANNU REV BIOPHYS, (2008), vol. 37, pages 353 - 73
    - YARDEN Y, "The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities", EUR J CANCER, (2001), vol. 37, no. 4, pages S3 - S8
    - JORISSEN RN; WALKER F; POULIOT N; GARRETT TP; WARD CW; BURGESS AW, "Epidermal growth factor receptor: mechanisms of activation and signalling", EXP CELL RES, (2003), vol. 284, pages 31 - 53
    - BUDAY L; DOWNWARD J, "Epidermal growth factor regulates p2lras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor", CELL, (1993), vol. 73, doi:doi:10.1016/0092-8674(93)90146-H, pages 611 - 20, XP027461467

DOI:   http://dx.doi.org/10.1016/0092-8674(93)90146-H
    - GALE NW; KAPLAN S; LOWENSTEIN EJ; SCHLESSINGER J; BAR-SAGI D, "Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras", NATURE, (1993), vol. 363, pages 88 - 92
    - SOLTOFF SP; CARRAWAY KL, III; PRIGENT SA; GULLICK WG; CANTLEY LC, "ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor", MOL CELL BIOL, (1994), vol. 14, pages 3550 - 8
    - PRIGENT SA; GULLICK WJ, "Identification of cErbB-3 binding sites for phosphatidylinositol 30-kinase and SHC using an EGF receptor/c-ErbB-3 chimera", EMBO J, (1994), vol. 13, pages 2831 - 41, XP002467288
    - UBERALL I; KOLAR Z; TROJANEC R; BERKOVCOVA J; HAJDUCH M, "The status and role of ErbB receptors in human cancer", EXP MOL PATHOL, (2008), vol. 84, pages 79 - 89, XP022553913
    - ROBERTSON SC; TYNAN J; DONOGHUE DJ, "RTK mutations and human syndromes: when good receptors turn bad", TRENDS GENET, (2000), vol. 16, doi:doi:10.1016/S0168-9525(00)02077-1, page 368, XP004215209

DOI:   http://dx.doi.org/10.1016/S0168-9525(00)02077-1
    - PATEL DK, "Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer", PHARMACOTHERAPY, (2008), vol. 28, pages 31S - 41S
    - MERCHANT ET AL., NATURE BIOTECHNOLOGY, (199807), vol. 16, pages 677 - 681
    - NISSIM A; HOOGENBOOM HR; TOMLINSON IM; FLYNN G; MIDGLEY C; LANE D; WINTER G, "Antibody fragments from a 'single pot' phage display library as immunochemical reagents", EMBO J., (19940201), vol. 13, no. 3, pages 692 - 8
    - KUBOTA T; NIWA R; SATOH M; AKINAGA S; SHITARA K; HANAI N, "Engineered therapeutic antibodies with improved effector functions", CANCER SCI, (200909), vol. 100, no. 9, doi:doi:10.1111/j.1349-7006.2009.01222.x, pages 1566 - 72, XP055108886

DOI:   http://dx.doi.org/10.1111/j.1349-7006.2009.01222.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.